Destiny Pharma plc
(“Destiny Pharma” or “the Company”)
Further information re AGM
Brighton, United Kingdom – 25 May 2021 – Destiny Pharma plc (AIM: DEST), a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections, as announced on 19 May 2021, will operate a virtual facility to allow Shareholders to listen in to the business of its Annual General Meeting (“AGM”) to be held at 11.00am BST on 3 June 2021.
The Company is using the Investor Meet Company platform. This platform will allow Shareholders to follow proceedings of the AGM and hear from the Company via the live presentation and Q&A session immediately following the AGM. The Company will also
provide an online recording, available on the Investor Meet Company platform and the Company’s website after the meeting.
Shareholders who wish to attend the online presentation should register for the event in advance via the following link:
Shareholders are invited to pre-submit questions either to firstname.lastname@example.org or online via the Investor Meet Company dashboard up until 17.00pm BST on 2 June 2021 or during the meeting itself via the Q&A function. Please include the Shareholder’s name and Shareholder Reference Number (which can be found on the share certificate or proxy form).
Shareholders wishing to vote at the AGM are strongly encouraged to do so by completing a form of proxy, appointing the Chairman of the AGM as their proxy. Shareholders will not be able to vote at the AGM over the online platform.
For further information, please contact:
Destiny Pharma plc
Neil Clark, CEO
Shaun Claydon, CFO
+44 (0) 127 370 4440
Optimum Strategic Communications
Mary Clark/ Shabnam Bashir/ Manel Mateus
+44 (0) 203 174 1789
finnCap Ltd (Nominated Advisor & Joint Broker)
Geoff Nash / Kate Bannatyne, Corporate Finance
Alice Lane, Corporate Broking
+44 (0) 207 220 0500
WG Partners (Joint Broker)
Nigel Barnes / Claes Spång / Nigel Birks
+44 (0) 203 705 9330
About Destiny Pharma
Destiny Pharma is a clinical stage, innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections. Its pipeline has novel microbiome-based biotherapeutics and XF drug clinical assets including NTCD-M3, a Phase 3 ready treatment for the prevention of C. difficile infection (CDI) recurrence which is the leading cause of hospital acquired infection in the US and also XF-73 nasal gel, which has recently completed a positive Phase 2b clinical trial targeting the prevention of post-surgical staphylococcal hospital infections including MRSA. It is also co-developing SPOR-COV, a
novel, biotherapeutic product for the prevention of COVID-19 and other viral respiratory infections and has earlier grant funded XF research projects.
For further information on the company, please visit https://www.destinypharma.com